Project Name: The Royal Marsden Partners Cancer Vanguard Oncology Pharmacy Service Improvement Joint Working Project (“JWP”)
Joint Working Project Summary: The Royal Marsden Hospital NHS Foundation Trust is the central coordinating hub of the Royal Marsden Partners Cancer Vanguard (“RMP”). The RMP is a network of public health, primary, secondary and community care NHS organisations working together in partnership to deliver cancer services across a 3.5 million catchment population of North West and South West London. There is increasing local medical oncology service demand and challenging oncology pharmacy workforce conditions across the RMP.
Novartis and the NHS team will work together on a JWP that combines resources, time and expertise to improve the quality of cancer patient care and patient satisfaction of the clinic service across the RMP catchment population. This will be achieved through:
the assessment of oncology pharmacy service functions and skill mix which support RMP clinical teams in the treatment and care of patients and the delivery / administration of chemotherapy / drug treatment; and
the improvement of oncology pharmacy service functions which support RMP clinical teams and the introduction of new models of care to further support the delivery / administration of chemotherapy / drug treatment across respective RMP sites.
The RMP will benefit from a Service Plan Report (“SPR”) which facilities the implementation of new oncology pharmacy functions and models of care led by two new roles:- Consultant Oncology Pharmacist and New Care Models Oncology Pharmacist, to improve the quality of cancer care and patient satisfaction. A JWP summary report and slide-set will showcase the improvement in the quality of cancer care and new models to provide evidence to the RMP for the long-term financial sustainable of the new service and new oncology pharmacy roles.
Novartis will benefit through developing a stronger partnership with the RMP and gain a richer understanding of the RMP oncology pharmacy service functions and service standards. This will enrich awareness when developing JWP’s with other NHS stakeholders and Cancer Vanguard sites. The JWP will also support patient access to optimal treatment strategies and improve patient management / outcomes.
Novartis and the NHS will combine financial resources to equally fund the Consultant Oncology Pharmacist and New Care Models Oncology Pharmacist post. The NHS will provide clinical oversight, training for the new roles along with the generation of the service protocol and patient satisfaction questionnaire. Novartis will provide project management and JWP documentation support. A project steering group will regularly review and track the progress and impact of this JWP via the generation of aggregated service level reports. At 12 months from the start of the JWP there will be a review of its progress and if the objectives and milestones are being met the JWP will continue into the second year. If the objectives and milestones are not being met, then the parties will enter into good faith discussions to decide whether to terminate the JWP.
Expected Patient Outcomes for this Project
The JWP will impact and touch over 500 advanced cancer patients, across the main RMP sites, to improve the quality of cancer care in line with the service standards and patient satisfaction of the solid tumour pathways in terms of:
quick access to the most appropriate chemotherapy / drug treatment at the right time for the right patient;
accurate chemotherapy / drug prescription verification, completion and assessment of full blood count and liver / renal function biochemical tests;
patient clinical assessment and reviews, by the RMP clinical / oncology pharmacy team, subject to tumour / hospital site;
patients offered the option to have their treatment delivered closer to home at satellite sites or the mobile chemotherapy bus service;
enhanced patient consultations and support materials given to patients to facilitate better disease understanding, self-management and medicines optimisation;
an aim to reduce the number of unplanned visits by patients to the Acute Oncology Service / Accident & Emergency departments.
Start Date: October 2017 with an expected duration to the end of October 2019.
Raigmore Hospital (NHS Highlands)
Project Name: Heart Failure Service Optimisation Project
Project Period: October 2017 – August 2018
Joint Working Project Summary: This joint working project is a Heart Failure patient review and optimisation for all diagnosed and symptomatic HF patients attending Raigmore Hospital, Inverness (NHS Highland).
Expected Patient Outcomes for this Project:
Targets for measurement and expected outcomes
Increase in the number of patients under the care of Raigmore Hospital Cardiology Service with heart failure, who have been admitted to hospital and reviewed
Increase in the number of appropriately diagnosed patients reviewed/triaged via this Joint Working project
Increase the proportion of patients with Left Ventricular Systolic Dysfunction (LVSD) receiving guideline-directed pharmacological therapies, excluding those with contraindication or intolerance
Start Date & Duration: October 2017 (12 months)
Belfast Trust Hospitals
Project Name: Creation of a Specialist Ambulatory Heart Failure (“HF”) service, located at Belfast City Hospital Project Period: October 2017 – October 2019
Joint Working Project Summary: The joint working project aims at establishing a day clinic, to be known as the Specialist Ambulatory Care HF Unit for HF Patients, to provide specialist clinical care on an out-patient basis
Expected patient outcomes for this project:
targets for measurement and expected outcomes
patient numbers seen by the HF Ambulatory Service;
patient satisfaction linked to the HF Ambulatory Service (PREMS);
increase the proportion of patients with LVSD receiving guideline-directed pharmacological therapies at 30 and 90 days post-discharge;
submission of business case for the future funding of the HF Ambulatory Service to the relevant NHS authorities